CA
NZ
UK
AU
IND
US
Aridis Pharmaceuticals (OTC:ARDS) was once a Nasdaq-listed developer of antibody therapies for serious infectious diseases, but the stock now trades for a fraction of a cent on the over-the-counter market in the last closing session. The company's public disclosure has thinned dramatically, and its …
Athersys, Inc (OTC:ATHXQ) spent the better part of two decades pursuing an ambitious idea: an off-the-shelf regenerative cell therapy, MultiStem, that could treat conditions ranging from stroke to acute respiratory distress. The science drew genuine interest, but theBusinesscould not outrun its cash needs, and …
● Interest reflects improving fundamentals and a supportive analyst view rather than a confirmed single-day catalyst.
Avitar, Inc (OTC:AVTI) was once a functioning medical-diagnostics manufacturer with a real product line, but the ticker now trades at essentially the lowest price a quote can register, a small fraction of a cent, with aMarket Valueof only a few hundred dollars. The company's …
Avitar, Inc (OTC:AVTI) was once a functioning medical-diagnostics manufacturer with a real product line, but the ticker now trades at essentially the lowest price a quote can register, a small fraction of a cent, with aMarket Valueof only a few hundred dollars. The company's …
● The stock's roughly 7.7% slide in the latest session does not map to a single, separately verified same-day catalyst.
Among the sub-penny cannabinoid names still listed over the counter, Alterola Biotech, Inc. (OTC:ABTI) stands out for a simple reason: unlike many peers that went silent years ago, it kept filing with the U.S. Securities and Exchange Commission well into the mid-2020s. That relative …
● A triple-digit percentage jump in a stock trading at a few cents is almost always a story about liquidity, not fundamentals, and Bio-Path Holdings.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) has been building a clinical case for stem-cell treatment of chronic back pain, yet its shares slipped in early-September trading even after reporting encouraging trial data earlier in 2026. The pullback in the BRTX ticker flagged by market feeds …
BioStem Technologies, Inc (NASDAQ:BSEM) has had an eventful 2026, capped by a move that many small companies aspire to but few complete: a graduation from over-the-counter trading to the Nasdaq Capital Market. With the shares recently pushing higher and the company stacking up distribution …
Please wait processing your request...